Latest Feed

TCT 2020

23-27 September 2020

Euro PCR 2020

19-22 May 2020

Svenska Kardiovaskulära Vårmötet

22-24 April 2020, Malmö Live

CTO Summit 2020

20-21 February 2020

New partnership with OrbusNeich...

An effective percutaneous treatment for refractory angina, a severely debilitating condition that affects millions globally.

Resulting from inadequate blood flow to the heart muscle, refractory angina (RA) can often cause recurrent and severe heart pain that may be difficult to manage through conventional drug, catheter, or surgical therapy.  RA patients typically experience significant disability and impaired quality of life with few options for relief or improvement in their symptoms.

The Neovasc Reducer has been shown to be a safe and effective treatment for RA. Using a procedure similar to a coronary stent implantation, the Reducer procedure uses standard catheter-based techniques.

As with any medical procedure, there are risks associated with the use of the Neovasc Reducer™ System, including but not limited to myocardial infarction, continued angina, and implant migration/dislodgement requiring medical intervention. For a complete list of complications, see the Instructions for Use.


  • Treats a large and growing population of patients suffering from refractory angina who have limited options
  • Currently CE Marked
  • COSIRA data showed patients treated with Reducer were 2.3 times more likely to see an improvement of two Canadian Cardiovascular Society (CCS) functional classification as compared to the control arm (n = 104, p value = 0.024).
    Note: The CCS class is a functional classification used to stratify the severity of angina by evaluating angina symptoms with activity levels.
    N Eng J Med 2015;372:519-527


The Society (European Society of Minimally Invasive Neurological Therapy) and its Foundation (European Foundation of Minimally Invasive Neurological Therapy) have been established in order to promote the benefits of minimally invasive neurological therapies in Europe through education, training and support for high quality scientific research.

ESMINT encourages and supports medical practitioners and scientists working to develop and improve minimally invasive methods for the treatment of neurological diseases. These methods will naturally evolve and currently involve the use of image guidance and medical devices such as endovascular catheters to perform treatments with minimum associated trauma.

The Society and Foundation promote the safe application of such techniques and their practice by suitably trained and competent practitioners throughout Europe. ESMINT encourages the setting of international standards for practice and research and encourages their use and appropriate implementation.

The Society (ESMINT) consists of individuals and groups of members working or training in geographical Europe in the field of minimally invasive neurological therapy. The members will determine the organisational structure of the Society and they will be expected to aspire to the highest standards of ethical and scientific medical practice.


Our Partners